Latest news

• AstraZeneca’s Calquence impresses in previously untreated CLL

  However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy  Brukinsa (zanubrutinib). ... It is also in clinical development for a host of other blood

• AstraZeneca wins FDA approval for Calquence in chronic lymphoma

  and small lymphocytic lymphoma (SLL), taking the fight to AbbVie/Johnson &Johnson’s Imbruvica. . ... The Chinese drugmaker's therapy is also in clinical development for CLL, SLL, follicular lymphoma and marginal zone lymphoma.

• BeiGene bags FDA approval for first product Brukinsa in lymphoma

  China’s BeiGene has claimed its first-ever product approval in the US, getting an FDA nod for its mantle cell lymphoma (MCL) therapy Brukinsa. ... It’s also under regulatory review in China and Europe for MCL, as well as being in clinical development

• BeiGene gets speedy US review for lymphoma drug zanubrutinib

  The US regulator awarded the status for zanubrutinib as a second-line treatment for mantle cell lymphoma (MCL), an aggressive type of non-Hodgkin’s lymphoma for which the drug also ... It’s also in late-stage testing for chronic lymphocytic leukaemia

• Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

  First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in